Parallax Volatility Advisers’s Sage Therapeutics SAGE Stock Holding History

Parallax Volatility Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-105,400	Closed	-$2.28M	–	2279
2023 Q4	$2.28M	Buy	105,400 +91,900	+681%	+$1.82M	﹤0.01%	1119
2023 Q3	$278K	Buy	+13,500	New	+$390K	﹤0.01%	1740
2022 Q4	–	Sell	-200	Closed	-$8K	–	3214
2022 Q3	$8K	Buy	+200	New	+$7.73K	﹤0.01%	2844
2022 Q2	–	Sell	-6,300	Closed	-$209K	–	3211
2022 Q1	$209K	Buy	+6,300	New	+$237K	﹤0.01%	2169
2021 Q3	–	Sell	-41,300	Closed	-$2.35M	–	2161
2021 Q2	$2.35M	Buy	+41,300	New	+$2.92M	﹤0.01%	832
2020 Q4	–	Sell	-18,000	Closed	-$1.1M	–	3133
2020 Q3	$1.1M	Buy	+18,000	New	+$912K	﹤0.01%	1955
2019 Q2	–	Sell	-78,000	Closed	-$12.4M	–	3564
2019 Q1	$12.4M	Buy	78,000 +70,500	+940%	+$10.2M	0.01%	422
2018 Q4	$718K	Buy	+7,500	New	+$858K	﹤0.01%	1414
2018 Q1	–	Sell	-10,000	Closed	-$1.65M	–	3924
2017 Q4	$1.65M	Buy	+10,000	New	+$970K	﹤0.01%	991
2016 Q4	–	Sell	-15,000	Closed	-$691K	–	3977
2016 Q3	$691K	Buy	+15,000	New	+$611K	﹤0.01%	1381

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parallax Volatility Advisers's SAGE Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Sage Therapeutics (SAGE) in Q4 2022, closing a stake of 7,386 shares — an estimated $289K sold.

Parallax Volatility Advisers first reported a position in SAGE in Q2 2017 and held it in 10 quarters. The position peaked at $1.92M in Q4 2018. 207 funds tracked by Wall St. Rank hold SAGE as of Q4 2022.

Parallax Volatility Advisers reported no remaining Sage Therapeutics position as of Q4 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 7,386 Sage Therapeutics shares in Q4 2022, an estimated $289K.
Parallax Volatility Advisers first reported a position in Sage Therapeutics in Q2 2017 and held it in 10 quarters.
Parallax Volatility Advisers's Sage Therapeutics position peaked at $1.92M in Q4 2018.
207 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.